US2017189432A1PendingUtilityA1

Pharmaceutical composition and method for regenerating myofibers in the treatment of muscle injuries

52
Assignee: LEAD BILLION LTDPriority: Oct 27, 2005Filed: Mar 17, 2017Published: Jul 6, 2017
Est. expiryOct 27, 2025(expired)· nominal 20-yr term from priority
A61P 43/00A61P 9/10A61P 9/00A61P 9/04A61K 31/56A61K 31/704A61K 35/34C07C 62/32A61K 31/7034A61K 9/0053A61K 9/0019
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A pharmaceutical composition and method for regenerating cardiomyocytes in treating or repairing heart muscle damages or injuries caused by an ischemic disease. The pharmaceutical composition contains an active ingredient compound with a backbone structure of Formula (I). The active ingredient compound is capable of (a) increasing viability of myogenic precursor cells to enable said precursor cells to survive through an absolute ischemic period; (b) reconstituting a damaged blood supply network in said heart region where said injured muscle is located; and (c) enhancing cardiomyogenic differentiation efficiency of said precursor cells down cardiac linage, said steps being performed simultaneously or in any particular order.

Claims

exact text as granted — not AI-modified
1 . A composition comprising substantially purified compounds of the following formulae: 
       
         
           
           
               
               
           
         
         and pharmaceutically acceptable salts thereof. 
       
     
     
         2 . The composition of  claim 1 , wherein the composition is a pharmaceutical composition comprising a pharmaceutically excipient. 
     
     
         3 . The pharmaceutical composition of  claim 2 , wherein the composition is formulated into a dosage form. 
     
     
         4 . The pharmaceutical composition of  claim 3 , wherein the dosage form is selected from the group consisting of tablet, capsule, injection solution, syrup, suspension and powder.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.